X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Molecular Therapy-Oncolytics

期刊標題檢索 MOL THER-ONCOLY 最新評論: How are you doing now? Have you published it? (2023-02-20)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Molecular Therapy-Oncolytics]您好,您是該頁面的第 43575 位訪客。

期刊簡介
期刊名稱Molecular Therapy-Oncolytics Molecular Therapy-Oncolytics

(According to latest JCR data, the title of this journal was changed to MOL THER ONCOLYTICS, which is now indexed in the JCR.)
LetPub Score
7.3
50 ratings
Rate

Reputation
8.2

Influence
6.1

Speed
9.0

期刊簡稱MOL THER-ONCOLYTICS
ISSN2372-7705
h-index12
CiteScore
CiteScoreSJRSNIPCiteScore Rank
10.901.4940.858
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Pharmacology (medical)
Q115 / 272
Category: Medicine
Subcategory: Oncology
Q151 / 404
Category: Medicine
Subcategory: Molecular Medicine
Q131 / 178
Category: Medicine
Subcategory: Cancer Research
Q144 / 230

自引率 (2023-2024)N.A.自引率趨勢
掲載範囲
Molecular Therapy — Oncolytics is an international, online-only, open access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer.
官方網站https://www.cell.com/molecular-therapy-family/oncolytics/latest-content
在線稿件提交https://mto.msubmit.net/cgi-bin/main.plex
開放訪問Yes
出版商Cell Press
主題領域Medicine
出版國/地區UNITED STATES
發行頻率
創刊年0
每年文章數144每年文章數趨勢
黃金OA百分比89.58%
OA Related Info
APC: Yes( USD3900; )
APC waiver:Check Notes
Other charges: No
Keywords: cell biology、oncolytics、molecular therapy、gene therapy、cancer
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q0

N/A
索引 (SCI or SCIE)
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2372-7705%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 6 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Molecular Therapy-Oncolytics】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    Nature CancerH-index: 0

    CiteScore: 31.10
    JAMA OncologyH-index: 41

    CiteScore: 37.50
    JAMA OncologyH-index: 61

    CiteScore: 37.50
    Trends in CancerH-index: 0

    CiteScore: 28.50
    Liver CancerH-index: 25

    CiteScore: 20.80
    Experimental Hematology & OncologyH-index: 0

    CiteScore: 12.60
    ESMO OpenH-index: 0

    CiteScore: 11.70
    Cancer Biology & MedicineH-index: 29

    CiteScore: 9.80
    Annual Review of Cancer BiologyH-index: 0

    CiteScore: 14.50
    CancersH-index: 53

    CiteScore: 8.00
    學科內最受檢索的期刊 頁面查看次數
    Cancers209502
    OncoTargets and Therapy183279
    Cancer Management and Research149109
    Journal of Oncology88245
    Cancer Biology & Medicine58478
    JAMA Oncology36961
    Liver Cancer34135
    Nature Cancer33324
    Translational Lung Cancer Research29416
    JAMA Oncology28793
  •  

    Molecular Therapy-Oncolytics Molecular Therapy-Oncolytics
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    3    4    下一頁    末頁  (頁
/4)
  [Molecular Therapy-Oncolytics] 的評論撰寫評論
作者: 黄土悦洋


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-02-20 20:28:21 評論於
How are you doing now? Have you published it?
(0) 讚! | 黄土悦洋

作者: 黄土悦洋


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-02-20 15:14:10 評論於
How is it going now? How long until the editor?
(0) 讚! | 黄土悦洋

作者: 奉天飞尘


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-12 13:49:13 評論於
I received a rejection letter one month after submission in December 2021, just like you. The reason given was the same as yours: "However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration." They didn't even specify which image, it's so frustrating
(0) 讚! | 奉天飞尘

作者: 乙亥酱大魔王


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-13 18:02:48 評論於
How should I upload the figure description section in PDF format?
(0) 讚! | 乙亥酱大魔王

作者: 玄虚世韵


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-05 09:10:35 評論於
Review speed: 2.0 | Submission acceptance rate: 95.0 Emphasized research direction: basic experience sharing: Article accepted on 2022-08-02, timeline as follows: Submission to MT was requested to transfer, agreed to transfer on 2022-02-09, Under Review on 2.23, Under Review on 3.18, Revision on 4.15, Major revision, Revised manuscript on 6.28, with editor; 7.5: under review; 7.12 under review, Decision in Process on 7.15, pre-accept (Revise) on 7.19, submitted after revising the format on 7.27, With Editor on 7.28. The review process is really slow. It's a major revision, but actually with very few changes. Two reviewers, one provided some comments and minor experiments; the other directly said it could be accepted. The revision was very friendly, and it was revised well ahead of the deadline by more than a month. After the revision, it still needs to be submitted to the editor, which is slow, taking 3 weeks for pre-acceptance
(0) 讚! | 玄虚世韵

作者: 小凯安吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-15 23:25:15 評論於
This magazine has never replied to the email he sent, and I have also written a reminder letter when the external review reached four months, but they did not reply to me
(0) 讚! | 小凯安吖

作者: Lucy Larkin


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-14 13:08:08 評論於
I sympathize with you, but you should provide detailed original records to support your argument
(0) 讚! | Lucy Larkin

作者: 西风浩宕


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-10 14:23:29 評論於
Review Speed: 12.0 | Submission Hit Rate: 5.0
Research Focus: Oncology
Experience Sharing: I would like to share the experience of submitting to this journal. After going through a total of 8 months, my paper was pre-accepted but eventually received a rejection email. The reason given was that they found a previously retracted article by the corresponding author, which raised doubts about the authenticity of my article. This guilt-by-association approach is unfair, as the authors of the retracted article and mine are completely different teams. Just because we share the same supervisor, my paper was rejected, and the back-and-forth process took a disgusting 8 months. If you have a history of retracted articles in your manuscript, I advise against submitting to this journal. Below is the final rejection letter:

Dear Dr. Fei,
Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration.

Best regards,
Yuman Fong, PhD
Editor-in-Chief, Molecular Therapy - Oncolytics

Timeline of Submission Events:
Jun 13, 2022	Editor Decision - Reject for History of Concerns
Jun 13, 2022	Author Submits Revision Confirmation
Jun 13, 2022	PDF Built and Requires Approval
Jun 09, 2022	Editor Decision - Pre-accept
May 18, 2022	Author Submits Revision Confirmation
May 18, 2022	PDF Built and Requires Approval
Mar 08, 2022	Editor Decision - Minor Revision
Oct 26, 2021	PDF Built and Requires Approval
Oct 26, 2021	Immediate Action Required-Unconfirmed Authorship
Oct 25, 2021	PDF Built and Requires Approval
Oct 25, 2021	Sent Back to Author Notice
Oct 25, 2021	Author Notice of Manuscript Number
Oct 25, 2021	PDF Built and Requires Approval
(0) 讚! | 西风浩宕

作者: 若山小可爱


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-04-17 15:17:46 評論於
Submission usually takes about 5 to 6 months to be accepted, with major revisions requested after the initial review taking 3 months, and acceptance after revisions taking around half a month. Hopefully this information can be helpful
(0) 讚! | 若山小可爱

作者: Bonnie Wyatt


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-04-14 08:53:17 評論於
Do you need to provide the original data?
(0) 讚! | Bonnie Wyatt

作者: 巴蜀友翠


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-08 09:24:32 評論於
Research focus: Tumor experience sharing: Submission on February 4th has been in "with editor" status. An email was sent on February 6th to inquire about the progress, but there was no response. On February 7th, the status was updated to "under review."
(0) 讚! | 巴蜀友翠

作者: 巴蜀友翠


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-07 17:13:26 評論於
I wanted to ask you what is the situation with your manuscript? Mine has been with the editor for over a month now, and there hasn't been any updates
(0) 讚! | 巴蜀友翠

作者: 巴蜀友翠


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-01-27 13:03:26 評論於
I would like to ask how long your "with editor" status has changed, and what is the next status after "with editor."
(0) 讚! | 巴蜀友翠

作者: 巴蜀友翠


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-01-27 08:26:00 評論於
How long did your "with editor" status last before submission? Did you ultimately get accepted?
(0) 讚! | 巴蜀友翠

作者: 东京茂典


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-01-24 13:29:07 評論於
Put a logo of your unit on it
(0) 讚! | 东京茂典

作者: 东风艳君


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-01-21 20:57:56 評論於
Could you please tell me how to create an "institutional letterhead" for the cover letter of this magazine? My submission was just rejected and they are asking for this
(0) 讚! | 东风艳君

作者: 巴蜀友翠


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-01-12 17:23:18 評論於
Research focus: tumor experience sharing. It's been almost half a month since submitting to the editor. Is the manuscript still in the editor's hands? Can I request a status update?
(0) 讚! | 巴蜀友翠

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 22:51:16 評論於
Possibly
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 19:26:41 評論於
The novelty of an article may be judged by searching for keywords
(0) 讚! | 维尔娜菲茨杰拉德

作者: 深渊兴业


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-28 19:33:37 評論於
Will the reviewers use the keywords I provide to search for innovation?
(0) 讚! | 深渊兴业

作者: 破戒阳平


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-27 17:42:13 評論於
How do reviewers use keywords for reviewing?
(0) 讚! | 破戒阳平

作者: 苍风思迪


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-18 09:02:21 評論於
The submission has been under review for nearly 6 weeks now. It went under review on November 8th, and the status was updated on December 13th, but it is still under review. I wonder if anyone else has encountered this situation before
(0) 讚! | 苍风思迪

作者: 奉天冰梦


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-01 20:08:20 評論於
I really want to urge submission, but I can't reach anyone. How did you all manage to contact the editor later on?
(0) 讚! | 奉天冰梦

作者: 奉天冰梦


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-01 12:28:45 評論於
Can it be expedited? How can I contact their editorial department?
(0) 讚! | 奉天冰梦

作者: 东风凯安


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-11-30 21:01:11 評論於
Just wait, it's very slow now. The first review took over 6 months and two reviewers have requested major revisions
(0) 讚! | 东风凯安

首頁    上一頁    1    2    3    4    下一頁    末頁  (頁
/4)

開始撰寫 [Molecular Therapy-Oncolytics] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*